PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27232667-5 2016 BMP-2 and dexamethasone in combination with TGF-beta1 or TGF-beta3 excelled at inducing chondrogenesis on SMSCs, HFPSCs and chondrocytes, as measured by glycosaminoglycans and collagen type II staining of pellets, quantitative glycosaminoglycan expression, quantitative PCR of cartilage signature genes and electron microscopy. Glycosaminoglycans 153-171 transforming growth factor beta 3 Homo sapiens 57-66 33827271-9 2021 The results showed that the scaffold delivered TGF-beta3 for up to 8 days of culture which resulted in 15-fold increase in GAG production, and 6-fold increase in collagen synthesis with respect to the No TGF-beta3 group. Glycosaminoglycans 123-126 transforming growth factor beta 3 Homo sapiens 47-56 29943542-5 2018 Addition of 100 ng/mL IFN-beta1a to regular TGF-beta3 chondrogenic differentiation medium could improve the concentration of GAG, increase the size of pellets, promote the formation of aggrecan and up-regulate the expression of CollangenII and Sox9. Glycosaminoglycans 125-128 transforming growth factor beta 3 Homo sapiens 44-53 33115953-6 2020 When Ad-MKX-transduced MSCs were seeded on TGF-beta3-conjugated decellularized meniscus scaffold (DMS) and inserted into experimental tears in meniscus explants, they increased glycosaminoglycan content, extracellular matrix interconnectivity, cell infiltration into the DMS, and improved biomechanical properties. Glycosaminoglycans 177-194 transforming growth factor beta 3 Homo sapiens 43-52 28161573-6 2017 Histological assessment of in vitro and subcutaneously implanted in vivo constructs demonstrated that CM-expanded cells followed by TGF-beta3 exposure resulted in highest cell proliferation, GAG accumulation, and collagen deposition. Glycosaminoglycans 191-194 transforming growth factor beta 3 Homo sapiens 132-141 27232667-5 2016 BMP-2 and dexamethasone in combination with TGF-beta1 or TGF-beta3 excelled at inducing chondrogenesis on SMSCs, HFPSCs and chondrocytes, as measured by glycosaminoglycans and collagen type II staining of pellets, quantitative glycosaminoglycan expression, quantitative PCR of cartilage signature genes and electron microscopy. Glycosaminoglycans 153-170 transforming growth factor beta 3 Homo sapiens 57-66 27079852-7 2016 Gene delivery of TGF-beta3 and BMP2 and subsequent cell-mediated expression of these therapeutic genes resulted in a significant increase in sulfated glycosaminoglycan and collagen production, particularly in the pTGF-beta3-pBMP2 codelivery group in comparison to the delivery of either pTGF-beta3 or pBMP2 in isolation. Glycosaminoglycans 150-167 transforming growth factor beta 3 Homo sapiens 17-26 26347860-8 2015 The TGF-beta3 group also produced a collagen type II and glycosaminoglycan-rich extracellular matrix, detected by immunohistochemistry, Alcian blue staining, and Safranin O staining suggesting robust chondrogenesis within the scaffold. Glycosaminoglycans 57-74 transforming growth factor beta 3 Homo sapiens 4-13 26783399-5 2016 However, the combined TGF-beta3/HS treatment resulted in a significant increase in GAG synthesis, cartilage matrix protein secretion, and cartilage-specific gene expression compared to cells treated with TGF-beta3 alone. Glycosaminoglycans 83-86 transforming growth factor beta 3 Homo sapiens 22-31 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 41-44 transforming growth factor beta 3 Homo sapiens 10-19 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 69-72 transforming growth factor beta 3 Homo sapiens 10-19 24284199-8 2014 Transient TGF-beta3 produced the highest GAG synthesis rate, highest GAG retention ratio, and the highest binding affinity; collagen synthesis was elevated in TGF-beta3 supplementation groups over control, with the highest binding affinity observed in the transient supplementation group; both COMP synthesis and retention were lower than those for GAG and collagen. Glycosaminoglycans 69-72 transforming growth factor beta 3 Homo sapiens 10-19 23579467-9 2013 Glycosaminoglycans contents were increased 217% by TGF-beta3 and 220% by BMP-6. Glycosaminoglycans 0-18 transforming growth factor beta 3 Homo sapiens 51-60 24491910-7 2014 Enhanced accumulation of cartilage-associated glycosaminoglycans by hMSCs incubated with TGF-beta3-loaded microspheres was seen and positive staining for collagen type II and proteoglycan confirmed successful in vitro chondrogenesis. Glycosaminoglycans 46-64 transforming growth factor beta 3 Homo sapiens 89-98 23839780-10 2013 In the culture with SB216763 + TGF-beta3, significantly more GAG was deposited (P < 0.05). Glycosaminoglycans 61-64 transforming growth factor beta 3 Homo sapiens 31-40 23474328-8 2013 Immunohistochemistry for TGFbeta3/DPSC constructs (n = 5/group) showed cartilage-like matrix formation with glycosaminoglycans. Glycosaminoglycans 108-126 transforming growth factor beta 3 Homo sapiens 25-33 22795539-6 2012 Also, the specific extracellular matrix of glycosaminoglycan (GAG) production of hMSCs adhered onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres increased more 2.5 times than control group. Glycosaminoglycans 43-60 transforming growth factor beta 3 Homo sapiens 127-137 22795539-6 2012 Also, the specific extracellular matrix of glycosaminoglycan (GAG) production of hMSCs adhered onto SOX9 gene plus heparinized TGF-beta 3 coated dexamethasone loaded PLGA microspheres increased more 2.5 times than control group. Glycosaminoglycans 62-65 transforming growth factor beta 3 Homo sapiens 127-137 21707438-9 2011 CDM supplemented with TGF-beta3 resulted in significantly higher glycosaminoglycan content (762.69+-220.79 ng/mg wet weight) and type II collagen (COL II) content (6.25+-1.64 ng/mg wet weight) at day 21 compared with untreated samples. Glycosaminoglycans 65-82 transforming growth factor beta 3 Homo sapiens 22-31 21866573-4 2012 TGFbeta3 + Dex stimulated degenerated human NP cells to proliferate and exhibit an anti-catabolic gene expression profile (with a decrease in ADAMTS5 and MMP1 compared to basal, and an increase in SOX9, decrease in ADAMTS5, MMP1, collagen I and collagen III compared to day 0), while NCA stimulated the greatest GAG per cell. Glycosaminoglycans 312-315 transforming growth factor beta 3 Homo sapiens 0-8 21866573-5 2012 We conclude that degenerated human NP cells exhibit regenerative potential, and that an optimal treatment will likely require treatments, such as TGFbeta3 + Dex, which were able to increase cell metabolism and reduce catabolism, as well as treatments with factors found in NC conditioned medium, that were able to produce high amounts of GAG per cell. Glycosaminoglycans 338-341 transforming growth factor beta 3 Homo sapiens 146-154 22370795-6 2012 At low concentrations of TGF-beta3 (1 ng/mL), HP acted to enhance chondrogenesis of both SDSCs and FPSCs, as evident by a 3-fold increase in Sox9 expression and a significant increase in glycosaminoglycan accumulation. Glycosaminoglycans 187-204 transforming growth factor beta 3 Homo sapiens 25-34 20408770-5 2010 Biochemical GAG measurement showed that production was significantly greater in TGF-beta3-treated AD-MSC in 3D culture versus untreated controls (p < 0.05). Glycosaminoglycans 12-15 transforming growth factor beta 3 Homo sapiens 80-89 19426117-5 2009 TGF-beta3 cultured with silk elastin-like polymer scaffold carrier exhibits significantly increased glycosaminoglycan and collagen content. Glycosaminoglycans 100-117 transforming growth factor beta 3 Homo sapiens 0-9 19700613-11 2009 Neutralizing TGF-beta3 antibody decreased the expression of the GAG-rich versican variants 2 to 8 fold in leiomyoma cells. Glycosaminoglycans 64-67 transforming growth factor beta 3 Homo sapiens 13-22 15639641-6 2005 Addition of transforming growth factor beta-3 and insulin like growth factor-1 increased collagen II expression and GAG synthesis in these SOX9 transduced cell pellets. Glycosaminoglycans 116-119 transforming growth factor beta 3 Homo sapiens 12-45 18454697-8 2009 The combination of the growth factors BMP-4 + TGF-beta 3 with the fibrochondrocyte coculture led to an increase in cell proliferation and GAG production compared to either treatment alone. Glycosaminoglycans 138-141 transforming growth factor beta 3 Homo sapiens 46-56 17404809-6 2008 By day 28, constructs cultured in the presence of TGF-beta3 exhibited significant increase in sulfated glycosaminoglycan and total collagen content up to 65 and 300%, respectively. Glycosaminoglycans 103-120 transforming growth factor beta 3 Homo sapiens 50-59 35573229-13 2022 Under induction of TGF-beta3, PBMSCs/DCBM composites expressed glycosaminoglycan (GAG), and the related gene expression also increased. Glycosaminoglycans 63-80 transforming growth factor beta 3 Homo sapiens 19-28 35573229-13 2022 Under induction of TGF-beta3, PBMSCs/DCBM composites expressed glycosaminoglycan (GAG), and the related gene expression also increased. Glycosaminoglycans 82-85 transforming growth factor beta 3 Homo sapiens 19-28